Latest "irbesartan amlodipine irbesartan Hypertension" News Stories

11:30 EDT 25th May 2015 | BioPortfolio

Here are the most relevant search results for "irbesartan amlodipine irbesartan Hypertension" found in our extensive news archives from over 250 global news sources.

More Information about irbesartan amlodipine irbesartan Hypertension on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about irbesartan amlodipine irbesartan Hypertension for you to read. Along with our medical data and news we also list irbesartan amlodipine irbesartan Hypertension Clinical Trials, which are updated daily. BioPortfolio also has a large database of irbesartan amlodipine irbesartan Hypertension Companies for you to search.

Showing "irbesartan amlodipine irbesartan Hypertension" News Articles 1–25 of 944

Extremely Relevant

FDA Approves Prestalia (amlodipine and perindopril) for Hypertension

January 21, 2015 -- Symplmed Pharmaceuticals announced that on January 21, 2015 the U.S. Food and Drug Administration approved Prestalia, a fixed dose combination of perindopril and amlodipine for the treatment of hypertension. Symplmed is excited...

Mylan introduces Amlodipine and Valsartan tablets in US to treat hypertension

Mylan has introduced Amlodipine and Valsartan Tablets, 5mg/160mg, 5mg/320mg, 10mg/160mg, 10 mg/320mg in the US market.

Relevant

Simultaneous Determination of Amlodipine and Its Counterion Besylate

Thermo Fisher Scientific has developed a simple, rapid, reliable, and accurate high-performance liquid chromatography (HPLC) method for the simultaneous determination of amlodipine and besylate in an amlodipine besylate drug substance.

FDA approves Symplmed's Prestalia combo for hypertension

Symplmed Pharmaceuticals LLC (Cincinnati, Ohio) said FDA approved an NDA for Prestalia to treat hypertension. The company plans to launch the fixed-dose combination of perindopril arginine plus amlodipine besylate this quarter through its bpCareConne...

FDA Approves Symplmed's Prestalia® for Treatment of Hypertension

Symplmed Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Prestalia® (perindopril arginine and amlodipine) tablets, licensed from Servier (Suresnes, France), for the treatment of hypertension. Prestalia, th...

Generic hypertension tablets released by Lupin in U.S.

Lupin Pharmaceuticals has made its Valsartan and Amlodipine tablets available in the U.S.  -More- 

Symplmed Pharmaceuticals approved for Prestalia

Ryan ChavisSymplmed Pharmaceuticals announced that the Food and Drug Administration approved Prestalia (perindopril arginine and amlodipine) tablets to treat hypertension.  read more

Teva launches generic Exforge tabs

Ryan ChavisTeva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension.    read more

US FDA approves Symplmed and Servier’s Prestalia

Privately-held US drugmaker Symplmed Pharmaceuticals says that the US Food and Drug Administration has approved Prestalia (perindopril arginine and amlodipine) tablets for the treatment of hypertension.

FDA Approvals, In Brief: Novartis’ Meningitis Vaccine Bexsero Gets Early Nod

Also, Rockwell’s iron deficiency treatment Triferic gains agency approval, but without a dose-sparing claim related to erythropoiesis-stimulating agents; Symplmed’s perindopril/amlodipine fixed-dose combination approved for hypertension.

Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey

Global Amlodipine Besylate Industry 2015-2020 Forecast Analysis Report

2015 Global Amlodipine Besylate Industry Research Report of 168 pages now readily available at DeepResearchReports.com database. Dallas, Texas (PRWEB) April 20, 2015 The 2015 Market Research Report on the Global Amlodipine Besylate Industry is a professional and in-depth study on the current state of the global Amlodipine Besylate Market with a focus on the Chinese situation. Major companies inc...

Resistant hypertension? Or failure to take blood pressure correctly?

I recently read a discussion by three hypertension specialists, Drs. Jan Basile, Dominic Sica and David Kountz, on how to treat resistant hypertension. Resistant hypertension is blood pressure that remains above goal despite treatment with three drugs, from different classes, one of which must be a diuretic. 10 to 15 percent of patients with high […]

RI Hospital Pulmonary Hypertension Center earns accreditation

(Lifespan) The Pulmonary Hypertension Center at Rhode Island Hospital is one of the nation's first centers of its kind to be accredited by the Pulmonary Hypertension Association. For those affected by pulmonary hypertension, accreditation assures the...

Pulmonary Hypertension Association Marks World PH Day on May 5 with a Worldwide Lifesaving Social Media Blitz

Silver Spring, Md. (PRWEB) April 27, 2015 On May 5, people living with pulmonary hypertension (PH) and their loved ones will ask their social media friends around the world to join their fight against a life-threatening disease too often dismissed...

Mylan Launches Generic Exforge® Tablets

POTTERS BAR, England and PITTSBURGH, March 31, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applic...

Prestalia perindopril/amlodipine regulatory update

Chronic insomniacs may face increased risk of hypertension

Insomniacs who take longer than 14 minutes to fall asleep face a greater risk of hypertension, according to new research in the American Heart Association journal Hypertension.

Pending EC decision: Lodipressine, amlodipine, Opinion date: 15-Jan-2015

Hypertension: Arteriovenous anastomosis—next panacea for hypertension?

The ROX CONTROL HTN study demonstrated the efficacy of arteriovenous coupler therapy in patients with resistant hypertension. However, one-third of the patients developed late ipsilateral venous stenosis, which required venoplasty or stenting. Future...

The AAPS Journal: Human Health Relevance of Pharmaceutically Active Compounds in Drinking Water

Type: Original PaperIn Canada, as many as 20 pharmaceutically active compounds (PhACs) have been detected in samples of treated drinking water. The presence of these PhACs in drinking water raises important questions as to the human health risk posed...

Hypertension: management

The choice of medicines used to manage hypertension depends on the patient’s age and ethnicity.

Hypertension and Information Systems

How data use and transparency improve hypertension control

Hypertension: Tight control of hypertension is safe in pregnant women

Hypertension: Lymphocyte adaptor protein puts the 'brakes' on hypertension


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks